135 related articles for article (PubMed ID: 34886743)
1. Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines.
Almazi JG; Alomari M; Belov L; Best OG; Shen Y; Graham ME; Mulligan SP; Christopherson RI
Nucleosides Nucleotides Nucleic Acids; 2022; 41(3):314-320. PubMed ID: 34886743
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine nucleoside induces accumulations of p53, p63 and p73 in the nuclei of human B-lymphoid cell lines, with cytosolic and mitochondrial increases in p53.
Almazi JG; Mactier S; Best OG; Crossett B; Mulligan SP; Christopherson RI
Proteomics Clin Appl; 2012 Jun; 6(5-6):279-90. PubMed ID: 22641291
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of fludarabine nucleoside against human Raji lymphoma cells.
Christopherson RI; Mactier S; Almazi JG; Kohnke PL; Best OG; Mulligan SP
Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):375-83. PubMed ID: 24940695
[TBL] [Abstract][Full Text] [Related]
4. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
5. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
6. Constitutively Photomorphogenic 1 Reduces the Sensitivity of Chronic Lymphocytic Leukemia Cells to Fludarabine Through Promotion of Ubiquitin-Mediated P53 Degradation.
Fu C; Shi X; Gong Y; Wan Y; Sun Z; Shi H; Wang Z; Marinaccio C; Crispino JD; Xu K
Cell Physiol Biochem; 2018; 50(6):2314-2328. PubMed ID: 30423551
[TBL] [Abstract][Full Text] [Related]
7. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
8. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas S; Bonavida B; Emmanouilides C
Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
[TBL] [Abstract][Full Text] [Related]
10. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
[TBL] [Abstract][Full Text] [Related]
11. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia.
Bellosillo B; Villamor N; Colomer D; Pons G; Montserrat E; Gil J
Blood; 1999 Oct; 94(8):2836-43. PubMed ID: 10515887
[TBL] [Abstract][Full Text] [Related]
13. The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
Leuk Lymphoma; 2013 Aug; 54(8):1840-3. PubMed ID: 23808769
[TBL] [Abstract][Full Text] [Related]
14. Advancing therapy for chronic lymphocytic leukemia--the role of rituximab.
Hillmen P
Semin Oncol; 2004 Feb; 31(1 Suppl 2):22-6. PubMed ID: 15042531
[TBL] [Abstract][Full Text] [Related]
15. Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Zemanova J; Hylse O; Collakova J; Vesely P; Oltova A; Borsky M; Zaprazna K; Kasparkova M; Janovska P; Verner J; Kohoutek J; Dzimkova M; Bryja V; Jaskova Z; Brychtova Y; Paruch K; Trbusek M
Oncotarget; 2016 Sep; 7(38):62091-62106. PubMed ID: 27556692
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine: a review of its use in non-Hodgkin's lymphoma.
Anderson VR; Perry CM
Drugs; 2007; 67(11):1633-55. PubMed ID: 17661532
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine induces differential expression of proteins in human leukemia and lymphoma cells.
Henrich S; Gez S; Crossett B; Mulligan SP; Christopherson RI
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):634-40. PubMed ID: 18600519
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
[TBL] [Abstract][Full Text] [Related]
19. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Di Gaetano N; Xiao Y; Erba E; Bassan R; Rambaldi A; Golay J; Introna M
Br J Haematol; 2001 Sep; 114(4):800-9. PubMed ID: 11564066
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.
Rosenwald A; Chuang EY; Davis RE; Wiestner A; Alizadeh AA; Arthur DC; Mitchell JB; Marti GE; Fowler DH; Wilson WH; Staudt LM
Blood; 2004 Sep; 104(5):1428-34. PubMed ID: 15138159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
